x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012426
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PGAM5 long isoform. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PGAM5 |
| UniProt No. | Q96HS1 |
| Gene ID | 192111 |
| Gene Description | Phosphoglycerate mutase family 5 is a mitochondrial serine/threonine protein phosphatase. PGAM5 is required for necrosis induced by TNF-α or reactive oxygen species. In addition, PGAM5 dephosphorylates FUNDC1 to induce mitophagy under mitochondrial stresses. PGAM5 is also essential for RIPK1-mediated mitophagy activation during extracellular matrix detachment of cancer cells. Furthermore, PGAM5 is cleaved by the protease presenilin-associated rhomboid-like protein in response to mitochondrial stresses treatment). The cleaved PGAM5, released from the mitochondrial membrane, dephosphorylates β-catenin in the cytosol leading to its stabilization. Increased levels of β-catenin stimulate mitochondrial biogenesis. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
